User Fee Bill Clears Senate Committee With Importation, Orphan Drug Amendments
Executive Summary
Highlighting the much-less-bipartisan atmosphere than the House, ranking member Burr votes against the package; US FDA’s advice to generic applicants could be contentious issue in reconciling the legislation between the two chambers.
You may also be interested in...
A Pivotal September For US FDA And Commissioner Califf
The month of September will be a crucial time for the US Food & Drug Administration and the legacy of its commissioner, Robert Califf. The agency will be taking several significant regulatory actions – but also crossing its fingers that legislation to assure its funding is secured.
US FDA User Fee Legislation: Is Sen. Burr’s ‘Clean’ Bill A Lifeline – Or A Wrench In The Works?
Sen. Richard Burr introduces a reauthorization bill without any policy changes, even ones he previously endorsed, saying it’s the clearest path forward now.
A Bipartisan Case Against US FDA User Fees?
Senators Richard Burr and Bernie Sanders do not typically agree on many issues. But during consideration of the US FDA user fee reauthorization package, both expressed concern that the increasing fees contribute to higher drug prices – and both voted against moving the package forward.